Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04079712 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 118 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Completion pushed from Aug 19, 2026 to Sep 2, 2027 Eligibility criteria expanded, about 32 words · Secondary endpoints: details revised at 3 of 4 entries · Site details revised at 9 of 46 sites Show 3 more changesShow less
    • Eligibility criteria expanded, about 32 words
    • Secondary endpoints: details revised at 3 of 4 entries
    • Site details revised at 9 of 46 sites
  2. Study sites revised (46)v117 See this version in full on ClinicalTrials.gov ↗
  3. 24 versions Re-verified since Mar 7, 2026, no change to tracked fieldsv93-v116
  4. Study sites revised (46)v92 See this version in full on ClinicalTrials.gov ↗
  5. Results first posted: Dec 12, 2025 Completion date: Jul 14, 2026 to Aug 19, 2026 · Secondary endpoints: details revised at 4 of 4 entriesv91 Show 2 more changesShow less
    • Completion date: Jul 14, 2026 to Aug 19, 2026
    • Secondary endpoints: details revised at 4 of 4 entries
Show 22 earlier versionsHide 22 earlier versions
  1. Study Status, Outcome Measures, Document Section, Participant Flow, Baseline Characteristics, Outcome Measures (Results), Adverse Events, More Informationv90
  2. Study sites revised (46)v89 See this version in full on ClinicalTrials.gov ↗
  3. Completion date: Mar 26, 2026 to Jul 14, 2026v88
  4. Re-verified, no change to tracked fieldsv87
  5. Completion date: Mar 25, 2026 to Mar 26, 2026v86
  6. Enrollment target: estimated 30 to confirmed 17 Primary completion date changed from estimate of Oct 1, 2025 to Jan 10, 2025 · Completion date: Oct 1, 2025 to Mar 25, 2026v85 Show 2 more changesShow less
    • Primary completion date changed from estimate of Oct 1, 2025 to Jan 10, 2025
    • Completion date: Oct 1, 2025 to Mar 25, 2026
  7. Study sites revised (46)v84 See this version in full on ClinicalTrials.gov ↗
  8. 3 versions Re-verified since Feb 6, 2025, no change to tracked fieldsv81-v83
  9. Study sites revised (46)v80 See this version in full on ClinicalTrials.gov ↗
  10. Primary and study completion dates: Oct 1, 2024 to Oct 1, 2025 Study sites: 47 to 46v79 Show 1 more changeShow less
    • Study sites: 47 to 46
  11. 2 versions Re-verified since Jul 2, 2024, no change to tracked fieldsv77-v78
  12. Study sites revised (47)v76 See this version in full on ClinicalTrials.gov ↗
  13. 2 versions Re-verified since Feb 6, 2024, no change to tracked fieldsv74-v75
  14. Study sites revised (47)v73 See this version in full on ClinicalTrials.gov ↗
  15. Re-verified, no change to tracked fieldsv72
  16. Primary and study completion dates: Oct 1, 2023 to Oct 1, 2024v71
  17. Start date: Jan 14, 2020 to Aug 6, 2020v70
  18. Re-verified, no change to tracked fieldsv69
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial studies how well the combination of XL184 (cabozantinib), nivolumab, and ipilimumab work in treating patients with poorly differentiated neuroendocrine tumors (i.e., neuroendocrine tumor that does not look like the normal tissue it arose from). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab and ipilimumab may shrink the cancer.
Trial Details
NCT Number NCT04079712
Lead Sponsor National Cancer Institute (NCI)
Conditions Metastatic Large Cell Neuroendocrine Carcinoma, Metastatic Neuroendocrine Carcinoma, Metastatic Neuroendocrine Neoplasm, Metastatic Small Cell Neuroendocrine Carcinoma
Enrollment 17 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov